SK Biopharm disclosed Monday that it signed a pharmaceutical supply contract with its subsidiary SK Life Science.
The contract is valued at 71.59 billion won ($53.2 million), equivalent to 10.1 percent of the company's 2025 sales.
The contract runs through Friday.
jiyoon436@heraldcorp.com
